PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis

2013-11-09
(Press-News.org) Contact information: Emily Eng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis ATLANTA, GA – Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. This data will be presented at the American Society of Nephrology's Kidney Week 2013 in Atlanta, GA.

Chronic kidney disease (CKD) is the slow loss of kidney function over time. The main function of the kidneys is to remove wastes and excess water from the body. When chronic kidney failure reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can accumulate in the body, and a patient will need to undergo hemodialysis (dialysis) – a machine that filters wastes, salts and fluid from the blood. A common problem for patients on dialysis is iron deficiency. The body needs a certain amount of iron for overall good health and healthy blood cells, but excess iron gradually builds up in tissues and organs, eventually damaging them. Standard, current care for dialysis patients with iron deficiency is to intravenously inject 100 mg of iron into the bloodstream. But this method can result in oxidative stress and harm to people on dialysis.

Steven Fishbane, MD, and Azzour Hazzan, MD from the North Shore-LIJ Health System's Division of Nephrology in New York, in collaboration with Ajay Singh, MD, associate professor at Harvard Medical School, conducted two Phase 3 trials, CRUISE-1 and CRUISE-2, which demonstrated, in 300 patients in each trial, that Triferic administered at each dialysis treatment for up to 48 weeks effectively delivers iron and maintains the body's hemoglobin concentration constant. Triferic is a novel iron compound that has a unique mode of action in that it is delivered to the patient via their dialysis treatment as opposed to intravenous delivery. Triferic gradually delivers iron to the bone marrow and maintains hemoglobin without the rapid flux of iron caused by intravenous injection.

"Up until now, iron deficiency in chronic kidney disease patients who undergo dialysis has been treated almost exclusively with intravenous iron, which injects a large amount of iron directly into the blood stream. This can potentially be toxic for patients," said Dr. Fishbane. "Our study is important and should be of interest to patients because it shows Triferic is effective in preventing iron deficiency without inducing iron overload in patients. It more closely mimics the slower natural way of absorbing iron and with additional studies, we might be able to show it is an improved and preferred treatment option."

INFORMATION:

About North Shore-LIJ Health System

One of the nation's largest healthcare systems, North Shore-LIJ delivers world-class clinical care throughout the New York metropolitan area, pioneering research at The Feinstein Institute for Medical Research and a visionary approach to medical education highlighted by the Hofstra North Shore-LIJ School of Medicine. North Shore-LIJ cares for people at every stage of life at 16 hospitals and nearly 400 outpatient physician practices throughout the region. North Shore-LIJ's owned hospitals and long-term care facilities house more than 6,000 beds, employ more than 10,000 nurses and have affiliations with more than 9,400 physicians. With a workforce of more than 46,000, North Shore-LIJ is the largest employer on Long Island and the third-largest private employer in New York City. For more information, go to http://www.northshorelij.com.

About American Society of Nephrology (ASN)

Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

ASN Kidney Week 2013, the largest nephrology meeting of its kind, will provide a forum for 14,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2013 will take place November 5 – 10, 2013 in Atlanta, GA.

END



ELSE PRESS RELEASES FROM THIS DATE:

Kidney Week 2013: New innovations in clinical science

2013-11-09
Kidney Week 2013: New innovations in clinical science Atlanta, GA (November 9, 2013)—A variety of recent studies highlight new and innovative research efforts that could help improve individuals' kidney health. Below are the findings of some of these studies, ...

Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease

2013-11-09
Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease Atlanta, GA (November 9, 2013)—Recently completed clinical trials highlight the potential of new therapies for individuals with kidney disease. Below are the ...

Kidney damage in first responders linked to 9/11

2013-11-09
Kidney damage in first responders linked to 9/11 New research findings of WTC-CHEST Program at Icahn School of Medicine at Mount Sinai presented at the 2013 American Society of Nephrology Meeting during National Kidney Week For ...

Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury

2013-11-09
Use of calcium-channel blocker and antibiotic associated with small increased risk of kidney injury Among older adults taking a calcium-channel blocker, simultaneous use of the antibiotic clarithromycin, compared with azithromycin, was associated ...

Gene hastens kidney disease progression in African-Americans

2013-11-09
Gene hastens kidney disease progression in African-Americans A gene variant common in African-Americans predicts that people with that gene who also have chronic kidney disease (CKD) are twice as likely to progress ...

Repurposed drug may be first targeted treatment for serious kidney disease

2013-11-09
Repurposed drug may be first targeted treatment for serious kidney disease Treatment with rheumatoid arthritis drug saved transplanted kidney in four patients, achieved remission in a fifth A drug approved for the treatment of rheumatoid arthritis may ...

Universals of conversation

2013-11-09
Universals of conversation Max Planck researchers found that words that signal problems with understanding are similar across languages A word like 'Huh?' —used when one has not caught what someone just said—appears to be universal: it is found to have very ...

High-energy physicists predict new family of four-quark objects

2013-11-09
High-energy physicists predict new family of four-quark objects New charged charmonium-like states observed at BESIII An international team of high-energy physicists says the discovery of an electrically charged subatomic particle called Zc(4020) is ...

NASA's TRMM satellite sees Super-typhoon Haiyan strike Philippines

2013-11-09
NASA's TRMM satellite sees Super-typhoon Haiyan strike Philippines VIDEO: NASA's TRMM satellite data on Nov. 8 at 00:19 UTC showed Haiyan had a well-defined eye surrounded ...

Snap to attention: Polymers that react and move to light

2013-11-09
Snap to attention: Polymers that react and move to light PITTSBURGH—Microvehicles and other devices that can change shape or move with no power source other than a beam of light may be possible through research led by the University of Pittsburgh. The researchers are ...

LAST 30 PRESS RELEASES:

International survey finds that support for climate interventions is tied to being hopeful and worried about climate change

Cambridge scientist launches free VR platform that eliminates the fear of public speaking

Open-Source AI matches top proprietary model in solving tough medical cases

Good fences make good neighbors (with carnivores)

NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer

Introducing our new cohort of AGA Future Leaders

Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help

Engineering excellence: Engineers with ONR ties elected to renowned scientific academy

New CRISPR-based diagnostic test detects pathogens in blood without amplification

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Growing solar: Optimizing agrivoltaic systems for crops and clean energy

Scientists discover how to reactivate cancer’s molecular “kill switch”

YouTube influencers: gaming’s best friend or worst enemy?

uOttawa scientists use light to unlock secret of atoms

NJIT mathematician to help map Earth's last frontier with Navy grant

NASA atmospheric wave-studying mission releases data from first 3,000 orbits

‘Microlightning’ in water droplets may have sparked life on Earth

Smoke from wildland-urban interface fires more deadly than remote wildfires

What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood

Protein accidentally lassos itself, helping explain unusual refolding behavior

With bird flu in raw milk, many in U.S. still do not know risks of consuming it

University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease

UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS

Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it

A closer look at biomolecular ‘silly putty’

Oxytocin system of breastfeeding affected in mothers with postnatal depression

Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles

Defensive firearm use is far less common than exposure to gun violence

Lifetime and past-year defensive gun use

Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults

[Press-News.org] Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis